126 related articles for article (PubMed ID: 38103202)
1. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
[TBL] [Abstract][Full Text] [Related]
2. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.
Halfmann PJ; Uraki R; Kuroda M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Kawaoka Y
EBioMedicine; 2023 Jul; 93():104677. PubMed ID: 37352827
[TBL] [Abstract][Full Text] [Related]
3. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
[TBL] [Abstract][Full Text] [Related]
4. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
6. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
[TBL] [Abstract][Full Text] [Related]
7. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
[TBL] [Abstract][Full Text] [Related]
8. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination.
Ju B; Fan Q; Liu C; Shen S; Wang M; Guo H; Zhou B; Ge X; Zhang Z
Cell Rep; 2023 Jun; 42(6):112532. PubMed ID: 37219999
[TBL] [Abstract][Full Text] [Related]
9. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
[TBL] [Abstract][Full Text] [Related]
10. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
[TBL] [Abstract][Full Text] [Related]
11. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
[TBL] [Abstract][Full Text] [Related]
12. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
[TBL] [Abstract][Full Text] [Related]
13. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
Boon J; Soudani N; Bricker T; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Suthar M; Ellebedy A; Davis-Gardner M
Res Sq; 2024 Feb; ():. PubMed ID: 38405749
[TBL] [Abstract][Full Text] [Related]
15. EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19.
Esmaeilzadeh A; Ebrahimi F; Jahani Maleki A; Siahmansouri A
Infection; 2024 Apr; 52(2):337-343. PubMed ID: 38170417
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Wang Q; Guo Y; Liu L; Schwanz LT; Li Z; Nair MS; Ho J; Zhang RM; Iketani S; Yu J; Huang Y; Qu Y; Valdez R; Lauring AS; Huang Y; Gordon A; Wang HH; Liu L; Ho DD
Nature; 2023 Dec; 624(7992):639-644. PubMed ID: 37871613
[TBL] [Abstract][Full Text] [Related]
17. Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters.
Abdelnabi R; Lassaunière R; Maes P; Weynand B; Neyts J
Viruses; 2024 Jan; 16(1):. PubMed ID: 38257822
[TBL] [Abstract][Full Text] [Related]
18. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
19. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
Curr Drug Targets; 2024 May; ():. PubMed ID: 38726782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
